Clinical Trials Browser

INDUSTRY × Breast Neoplasms × capivasertib × Clear all

Breast Neoplasms, Melanoma

NCT06982521 2026-03-03

ReDiscover-2

Phase 3 Recruiting

540 enrolled

Breast

Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06635447 2026-01-13

CAPItrue

Phase 3 Recruiting

300 enrolled

Breast

Breast Neoplasms, Disease Progression

NCT06764186 2026-01-13

CAPItana

Phase 3 Active not recruiting

101 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

923 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1 Completed

285 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Clinical Trials

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

ReDiscover-2

BEGONIA

CAPItrue

CAPItana

ELEVATE

CAPItello-290

DB-08

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules